<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>341</serviceExecutionTime><Drug id="27410"><DrugName>Quattvaxem</DrugName><DrugNamesKey><Name id="42842091">Quattvaxem</Name></DrugNamesKey><DrugSynonyms><Name><Value>DPT-Hib vaccine, Chiron</Value></Name><Name><Value>DTP-Hib vaccine, Chiron</Value></Name><Name><Value>Quattvaxem</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>DTwPHib-CRM197 conjugate vaccine</Value></Name><Name><Value>diphtheria, tetanus, pertussis, Haemophilus influenzae b vaccine (CRM-197 adjuvant), Chiron</Value></Name></DrugSynonyms><CompanyOriginator id="15385">Chiron Corp</CompanyOriginator><CompaniesPrimary><Company id="15385">Chiron Corp</Company></CompaniesPrimary><CrossReferences><SourceEntity id="27410" type="Drug"><TargetEntity id="449940" type="siDrug">DTwP Hib-CRM197</TargetEntity></SourceEntity><SourceEntity id="15385" type="Company"><TargetEntity id="5036161975" type="organizationId">Chiron Corp</TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"/></SourceEntity><SourceEntity id="47" type="ciIndication"><TargetEntity id="A37" type="ICD10"/><TargetEntity id="033" type="ICD9"/><TargetEntity id="10034738" type="MEDDRA"/><TargetEntity id="D014917" type="MeSH"/><TargetEntity id="1489" type="ORPHANET"/><TargetEntity id="-320620987" type="omicsDisease"/><TargetEntity id="2337" type="siCondition"/></SourceEntity><SourceEntity id="72" type="ciIndication"><TargetEntity id="10043376" type="MEDDRA"/><TargetEntity id="D013742" type="MeSH"/><TargetEntity id="3299" type="ORPHANET"/><TargetEntity id="-687302618" type="omicsDisease"/><TargetEntity id="816" type="siCondition"/></SourceEntity><SourceEntity id="81" type="ciIndication"><TargetEntity id="A36" type="ICD10"/><TargetEntity id="10013023" type="MEDDRA"/><TargetEntity id="D004165" type="MeSH"/><TargetEntity id="1679" type="ORPHANET"/><TargetEntity id="-360770994" type="omicsDisease"/><TargetEntity id="3234" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bordetella pertussis infection - Central America - Apr-2006</FirstLaunched><FirstLaunched>Bordetella pertussis infection - Italy - Apr-2006</FirstLaunched><FirstLaunched>Bordetella pertussis infection - Middle East - Apr-2006</FirstLaunched><FirstLaunched>Bordetella pertussis infection - South America - Apr-2006</FirstLaunched><FirstLaunched>Clostridium tetani infection - Italy - Apr-2006</FirstLaunched><FirstLaunched>Corynebacterium diphtheriae infection - Central America - Apr-2006</FirstLaunched><FirstLaunched>Corynebacterium diphtheriae infection - Italy - Apr-2006</FirstLaunched><FirstLaunched>Corynebacterium diphtheriae infection - Middle East - Apr-2006</FirstLaunched><FirstLaunched>Corynebacterium diphtheriae infection - South America - Apr-2006</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - Central America - Apr-2006</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - Italy - Apr-2006</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - Middle East - Apr-2006</FirstLaunched><FirstLaunched>Haemophilus influenzae infection - South America - Apr-2006</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="47">Bordetella pertussis infection</Indication><Indication id="72">Clostridium tetani infection</Indication><Indication id="81">Corynebacterium diphtheriae infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="12375">Toxoid vaccine</Action><Action id="12378">Prophylactic vaccine</Action><Action id="12371">Subunit vaccine</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="596">Injectable formulation</Technology></Technologies><LastModificationDate>2019-04-04T11:40:31.000Z</LastModificationDate><ChangeDateLast>2018-08-07T00:00:00.000Z</ChangeDateLast><AddedDate>2000-02-21T16:59:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15385" linkType="Company"&gt;Chiron&lt;/ulink&gt; (now part of &lt;ulink linkID="1020606" linkType="Company"&gt;Novartis Vaccines &amp;amp; Diagnostics&lt;/ulink&gt;) has developed Quattvaxem, a DTP-Hib vaccine in an injectable liquid formulation,  for the prevention of diphtheria, tetanus, pertussis and Haemophilus influenzae B (Hib) infection [&lt;ulink linkID="356554" linkType="reference"&gt;356554&lt;/ulink&gt;].  By July 2002, the vaccine had been approved in Italy [&lt;ulink linkID="459406" linkType="reference"&gt;459406&lt;/ulink&gt;]; by 2006, it had been launched in Latin America, Middle East and Italy for diphtheria,  pertussis, Hib infection and tetanus [&lt;ulink linkID="664577" linkType="Reference"&gt;664577&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By March 2002, the vaccine had entered phase III trials [&lt;ulink linkID="445353" linkType="reference"&gt;445353&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2005, clinical data were published from a trial in 261 infants showing that Quattvaxem vaccination elicited higher anti-Hib responses than three similar vaccines containing lower amounts of the CRM-197-Hib conjugate antigen. All participants showed responses to diphtheria and tetanus antigens and over 80% showed responses to pertussis antigen [&lt;ulink linkID="654271" linkType="Reference"&gt;654271&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2003, clinical data were published showing that Quattvaxem was safe and immunogenic in infants. It elicited an antibody response in more individuals than a comparator regime involving administration of separate DTP and Hib vaccines [&lt;ulink linkID="654283" linkType="Reference"&gt;654283&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of February 2000, the vaccine was in phase II trials [&lt;ulink linkID="356554" linkType="reference"&gt;356554&lt;/ulink&gt;], [&lt;ulink linkID="356553" linkType="reference"&gt;356553&lt;/ulink&gt;]. These were ongoing in June 2001 [&lt;ulink linkID="413598" linkType="reference"&gt;413598&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2006-04-20T00:00:00.000Z</StatusDate><Source id="664577" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2003-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2003-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2003-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2003-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2000-02-21T16:59:24.000Z</StatusDate><Source id="356554" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2000-02-21T16:59:24.000Z</StatusDate><Source id="356554" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2000-02-21T16:59:24.000Z</StatusDate><Source id="356554" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2000-02-21T16:59:24.000Z</StatusDate><Source id="356554" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2002-03-01T00:00:00.000Z</StatusDate><Source id="445353" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2002-03-01T00:00:00.000Z</StatusDate><Source id="445353" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2002-03-01T00:00:00.000Z</StatusDate><Source id="445353" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2002-03-01T00:00:00.000Z</StatusDate><Source id="445353" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate>2002-07-29T00:00:00.000Z</StatusDate><Source id="459406" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate>2002-07-29T00:00:00.000Z</StatusDate><Source id="459406" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate>2002-07-29T00:00:00.000Z</StatusDate><Source id="459406" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate>2002-07-29T00:00:00.000Z</StatusDate><Source id="459406" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1918625" number="WO-2009010877" title="Conjugate purification"/><PatentFamily id="604057" number="US-04673574" title="Immunogenic conjugates"/><PatentFamily id="888969" number="WO-2009074867" title="Analysis of mixtures including proteins"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsubishi Chemical Holdings Corp" id="1022450"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nuron Biotech Inc" id="1061492"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Rochester" id="20669"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>